Wells Fargo Upgrades Relay Therapeutics and Zymeworks Stocks
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.
/ 1 item
#RLAY↓